

---

## Answers to CME examination

Identification No. JC0419

April 2019 issue of the Journal of the American Academy of Dermatology.

Shields BE, Rosenbach M, Brown-Joel Z, Berger AP, Ford BA, Wanat KA. J Am Acad Dermatol 2019;80:869-80.

1. e

2. e

---

# **JAAD Game Changers: Dupilumab therapy provides clinically meaningful improvement in patient- reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)**



Eden Lake, MD  
Maywood, Illinois

### ***Capsule Summary***

- The substantial patient burden associated with moderate to severe atopic dermatitis demonstrates need for effective therapies.
- Dupilumab resulted in significant and clinically relevant improvements in patient-reported outcomes assessing symptoms and health-related quality of life.
- Dupilumab effects on patient-reported outcomes complemented clinical measures, demonstrating efficacy for atopic dermatitis across multiple domains important to patients.

### ***How did this article change the practice of dermatology?***

This study demonstrated significant improvement of atopic dermatitis with dupilumab and established improved outcomes at dosing of 300 mg.<sup>1</sup>

---

Funding sources: None

Conflicts of interest: None disclosed

Accepted for publication October 25, 2018.

Correspondence to: Eden Lake, MD, Dermatology Division, Loyola University Medical Center, 321 N La Grange Rd, La Grange Park, IL 60526-5622. E-mail: [Eden.Lake@lumc.edu](mailto:Eden.Lake@lumc.edu).

© 2018 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.

<https://doi.org/10.1016/j.jaad.2018.10.051>

### **REFERENCE**

1. Simpson EL, Gadhari A, Worm M, et al. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). *J Am Acad Dermatol*. 2016;75(3):506-515.